secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063938
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts
--------------------------------------------------------------------------------

- Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.
- Net loss of $72.2M in Q1 2025; R&D expenses $70.9M (down from $140.2M Q4 2024 incl. one-time $75M license payment).
- Over 300 patients enrolled in darovasertib + crizotinib 1L MUM registrational trial; median PFS readout targeted by YE 2025.
- FDA Breakthrough Therapy designation for neoadjuvant darovasertib in primary UM; Phase 3 design finalized after Type D meeting.
- Three IND filings targeted in 2025: PRMT5 (IDE892), B7H3/PTK7 ADC (IDE034), KAT6/7 (IDE574); IDE849 Phase 1 started in US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/0000950170-25-063938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017025063938/idya-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer